Recent performance snapshot

Guardant Health (GH) has drawn fresh attention after recent price moves, with the stock up around 47% over the past month and roughly 38% over the past 3 months.

That performance comes against a backdrop of annual revenue of about US$1.1b and a reported net loss of US$433.2m. These are figures that many investors will weigh when assessing whether the recent momentum aligns with the company’s underlying financial profile.

Looking beyond the recent surge, Guardant Health’s 1-year total shareholder return of about 207% and very large 3-year total shareholder return suggest strong longer term momentum around changing expectations for its growth and risk profile.

If Guardant Health’s recent move has you looking across the sector, it could be worth scanning for other fast growing healthcare AI opportunities through the 40 healthcare AI stocks.

With Guardant Health trading near its analyst price target and an estimated intrinsic value suggesting a sizeable discount, the key question is whether there is still a buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 1% Overvalued

The most widely followed narrative puts Guardant Health’s fair value at about $128.33, just under the last close of $129.14. This points to a finely balanced pricing story built on detailed long term forecasts.

Accelerating adoption of non-invasive blood-based cancer diagnostics is driving substantial growth across Guardant Health's key product lines (Guardant360 Liquid, Reveal, and Shield), expanding the company's total addressable market and supporting high double-digit revenue growth, with continued strong volume momentum and share gains documented for both new and established oncology applications.

Want to see what justifies this tight gap between price and fair value? The narrative leans on aggressive revenue expansion, shifting margins and a rich future earnings multiple. Curious which assumptions carry the most weight in that model and how sensitive they are to execution?

Result: Fair Value of $128.33 (OVERVALUED)

However, there is still the risk that high ongoing spending and potential payer pushback on Shield could delay profitability and weaken the assumptions behind this tight valuation gap.

Another view: DCF points to a different story

While the consensus narrative sees Guardant Health as about 1% overvalued at $128.33 per share, the SWS DCF model points in the opposite direction, with an estimated future cash flow value of $209.53 and the stock trading at a 38.4% discount. Which set of assumptions do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Guardant Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 1 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on value, sentiment and future cash flows, the next move is on you, so weigh the trade off between potential upside and downside by checking the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Guardant Health caught your attention, do not stop here. Broaden your watchlist with other focused ideas that could sharpen your next investing move.

• Spot potential mispricings early by scanning companies that screen as 1 high quality undervalued stocks before they move onto everyone else's radar.
• Strengthen your income options by zeroing in on stocks that qualify as 10 dividend fortresses, where yields and consistency both matter.
• Reduce surprises by focusing on companies highlighted in the 62 resilient stocks with low risk scores that score well on resilience and financial risk factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.